With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Weight loss drugmaker Novo Nordisk ... NVO said the leadership transition was made in light of the company’s recent market challenges and the performance of its stock since mid-2024.

Adventurous speculators interested in a quick-strike opportunity may want to set their sights on Novo Nordisk (NYSE: NVO ).

In my view, Novo Nordisk's stock is attractive regardless of its recent shopping spree. Here's one reason. Its forward price-to-earnings (P/E) ratio is 19.6 at this writing, while the average for ...

Novo Nordisk and its chief executive are parting ways after recent market challenges and a sharp decline in the company's share price over the past 12 months. Lars Fruergaard Jorgensen, who has ...

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 ... Before you buy stock in Novo Nordisk, consider this: ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Novo Nordisk and its chief executive are parting ways after recent market challenges and a sharp decline in the company's share price over the past 12 ... This Stock Is Cheap, High-Yielding, ...

Novo Nordisk has a GLP-1 Ozempic pill. That's both good and bad news for Novo Nordisk stock. Skip to main content. Boydton, VA. Boydton, VA. Local News. Subscriptions; Animals. Finance ...